HJURP and prostate cancer: As revealed by the promoter methylation status chart, HJURP was hypomethylated in bladder urothelial carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, prostate cancer and testicular germ cell carcinoma, etc. (Fig. 3A–E).